A novel online tool called INSIGHT© offers a machine learning-based approach when prescribing sodium-glucose cotransporter-2 (SGLT2) inhibitors to maximize the benefit for patients with Type 2 diabetes.
Image credit: Max Pixel, CC0 Public Domain
The study, led by Yale researcher Rohan Khera, MD, MS, appears in the journal Diabetes Care. The study’s first author is Yale Clinical Fellow, Evangelos Oikonomou, MD, DPhil, who works with Khera at the CarDS Lab.
Evidence from the CANVAS and CREDENCE trials suggests that SGLT2 inhibitors such as canagliflozin reduce the risk of hospitalizations and death from atherosclerotic cardiovascular disease (ASCVD) in adults with Type 2 diabetes. However, canagliflozin prescriptions are expensive and widely underutilized.
The study describes an individualized approach which addresses a common clinical question for ASCVD risk management: Which patients with Type 2 diabetes and an elevated risk for cardiovascular disease are most likely to benefit from canagliflozin? INSIGHT’s algorithms use distinct patient phenotypes such as the duration of Type 2 diabetes, elevated blood pressure or hypertension, smoking habits, and cholesterol levels to identify such patients.
Rather than relying on observations or assumptions, machine learning enables researchers to analyze vast amounts of clinical data and discover patterns or clues that might otherwise have been overlooked. In this instance, a machine learning approach helps isolate the characteristics that best determine the effects of canagliflozin for CV risk reduction. The study notes that one-third of patients were identified who would benefit the most from this therapy, which may help more targeted implementation studies.
The authors collected data from over 10,000 patients using an open science project known as the Yale University Open Data Access Project. The findings were first presented at the 2021 Northwestern Cardiovascular Young Investigators' Forum, where Oikonomou received an award for his presentation, “A Machine Learning Approach to Individualize the Cardiovascular Benefits of Canagliflozin Based on Participant-level Analyses of the CANVAS Trials.”
Source: Yale University